SAEID BABAEI, PhD, MBA
Dr. Babaei’s track record includes over 20 years of academic and corporate experience, during which he has led a number of novel and first-in-class product opportunities to either commercialization or to late-stage development. He brings a tremendous business foresight having closed over 15 licensing and strategic alliance transactions, as well as raising over $50 million in equity financing.Dr. Babaei is currently the President and CEO at AbCelex Technologies, a Canadian biotechnology company specializing in discovery, development and commercialization of antibody-based products for animal and human health.
Prior to co-founding AbCelex, he headed business development and strategic alliance management at the Centre for Drug Research and Development. Prior to that he was the VP of business development at Aptose Biosciences Inc. (formerly known as Lorus Therapeutics), where he was responsible for product and technology in- and out-licensing, strategic planning and corporate finance. During his tenure at Aptose, he successfully out-licensed a Phase III cancer immunotherapy program to a US-based biopharma, which resulted in over $12 million upfront and potential milestone payment, high double digit tiered royalty, and an equity investment in the licensee. Prior to Lorus, Saeid served as Director, corporate and business development for Northern Therapeutics where he negotiated and executed a variety of key deal transactions, which included the out-licensing of adult stem-based gene therapy program to United Therapeutics, in-licensing of enabling technologies and the establishment of number of key R&D collaborations. He has served as President of the Life Sciences division at AngioCell, providing partnering support and advice to a range of clients on licensing, M&A, pipeline valuation, strategic planning and project financing.
Dr. Babaei holds a PhD and an executive MBA, both from the University of Toronto. He has authored over 50 publications including research papers, conference presentations and patents. He currently serves as Chairman of the Board of Directors of BriaCell Therapeutics and former Chairman of Vaxil Bio, both clinical stage immuno-oncology companies listed on TSX-V.